Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Thrombomodulin alfa prevents the decrease in platelet aggregation in rat models of disseminated intravascular coagulation.

Kimpara N, Tawara S, Kawasaki K.

Thromb Res. 2019 Jul;179:73-80. doi: 10.1016/j.thromres.2019.05.002. Epub 2019 May 4.

PMID:
31096113
2.

Immunological responses against hepatitis B virus in human peripheral blood mononuclear cell-engrafted mice.

Aono S, Tatsumi T, Yoshioka T, Tawara S, Nishio A, Onishi Y, Fukutomi K, Nakabori T, Kodama T, Shigekawa M, Hikita H, Sakamori R, Takahashi T, Suemizu H, Takehara T.

Biochem Biophys Res Commun. 2018 Sep 10;503(3):1457-1464. doi: 10.1016/j.bbrc.2018.07.063. Epub 2018 Jul 20.

PMID:
30033102
3.

Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro.

Tanaka K, Tawara S, Tsuruta K, Hoppensteadt D, Fareed J.

Clin Appl Thromb Hemost. 2018 Sep;24(6):859-866. doi: 10.1177/1076029618770274. Epub 2018 Apr 22.

PMID:
29683037
4.

Thrombomodulin alfa attenuates the procoagulant effect and cytotoxicity of extracellular histones through the promotion of protein C activation.

Osada K, Minami T, Arioka T, Sakai T, Tawara S, Kawasaki K, Fareed J, Matsuzaki O.

Thromb Res. 2017 Dec;160:51-57. doi: 10.1016/j.thromres.2017.10.019. Epub 2017 Oct 27.

PMID:
29101790
5.

Thrombomodulin alfa attenuates thrombin-induced leakage of antithrombin through suppression of endothelial vascular hyperpermeability.

Arioka T, Tawara S, Sata M, Kawasaki K, Matsuzaki O.

Thromb Res. 2017 Sep;157:170-172. doi: 10.1016/j.thromres.2017.07.014. Epub 2017 Jul 15. No abstract available.

PMID:
28779617
6.

Anti-inflammatory and anti-fibrinolytic effects of thrombomodulin alfa through carboxypeptidase B2 in the presence of thrombin.

Tawara S, Sakai T, Matsuzaki O.

Thromb Res. 2016 Nov;147:72-79. doi: 10.1016/j.thromres.2016.09.011. Epub 2016 Sep 17.

PMID:
27693845
7.

Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.

Tawara S, Tatsumi T, Iio S, Kobayashi I, Shigekawa M, Hikita H, Sakamori R, Hiramatsu N, Miyoshi E, Takehara T.

PLoS One. 2016 Mar 22;11(3):e0151828. doi: 10.1371/journal.pone.0151828. eCollection 2016.

8.

Hypertrophic olivary degeneration with an egg-shaped appearance.

Kosaka T, Asao C, Tawara S.

Intern Med. 2014;53(23):2751-2. Epub 2014 Dec 1. No abstract available.

9.

[An autopsy case with progressive muscular atrophy: an subtype of lower motor predominant amyotrophic lateral sclerosis].

Kosaka T, Tawara S, Harada M, Takahashi T, Murayama T.

Brain Nerve. 2014 Nov;66(11):1405-9. doi: 10.11477/mf.1416200047. Japanese.

PMID:
25407076
10.

[Disease animal models for drug research and development].

Arai H, Masumi S, Tawara S, Itoh S, Nakahara Y, Morimoto N, Kobayashi N, Itano Y, Yamaguchi T, Niwa K, Seki J, Shigaki T, Nakamura K.

Nihon Yakurigaku Zasshi. 2014 Sep;144(3):126-32. Japanese. No abstract available.

PMID:
25213613
11.

[Requirements for the license-out of drug candidates to pharmaceutical companies].

Tawara S, Kobayashi N, Arai H, Masumi S, Itoh S, Nakahara Y, Morimoto N, Itano Y, Yamaguchi T, Niwa K, Seki J, Nakamura K.

Nihon Yakurigaku Zasshi. 2014 Apr;143(4):198-202. Review. Japanese. No abstract available.

PMID:
24717609
12.

Post-transplant lymphoproliferative disorder of the ileum diagnosed by double-balloon enteroscopy.

Tawara S, Shinzaki S, Nishida T, Kato M, Hiyama S, Inoue T, Iijima H, Tsujii M, Takehara T.

Endoscopy. 2013;45 Suppl 2 UCTN:E380-1. doi: 10.1055/s-0033-1344828. Epub 2013 Nov 27. No abstract available.

PMID:
24285058
13.

Use of patients' mobile phones to store and share personal health information: results of a questionnaire survey.

Tawara S, Yonemochi Y, Kosaka T, Kouzaki Y, Takita T, Tsuruta T.

Intern Med. 2013;52(7):751-6. Epub 2013 Apr 1.

14.

Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.

Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Kobori M, Katou M, Tawara S, Kawabata S, Furuichi K.

Biochem Biophys Res Commun. 2012 Sep 7;425(4):711-6. doi: 10.1016/j.bbrc.2012.07.103. Epub 2012 Jul 27.

PMID:
22842455
15.

[Development of a learning outcome creation program to enhance the competence of public health nurses part of action research to contribute to the local community].

Okamoto R, Tanigaki S, Iwamoto S, Kusano E, Koide K, Hatono Y, Okada M, Shiomi M, Kotera S, Tawara S, Hoshita Y, Fukukawa K, Kayano H, Onoi M.

Nihon Koshu Eisei Zasshi. 2011 Sep;58(9):778-92. Japanese.

PMID:
22171498
16.

Unique profiles of changes in cell membrane fluidity during ethanol-induced yeast-to-pseudohyphal transition in Candida tropicalis.

Suzuki T, Kono K, Tawara S, Fujimura T, Ito T, Omi K, Ohbuchi K, Komatsu Y, Sakaguchi S, Kamihara T.

J Gen Appl Microbiol. 2010 Aug;56(4):321-9.

17.

Effect of paraquat-induced oxidative stress on insulin regulation of insulin-like growth factor-binding protein-1 gene expression.

Kimura K, Katsumata Y, Ozawa T, Tawara S, Igarashi K, Cho Y, Shibata N, Hakuno F, Takahashi S, Takenaka A.

J Clin Biochem Nutr. 2010 Mar;46(2):157-67. doi: 10.3164/jcbn.09-97. Epub 2010 Feb 27.

18.

[Opioid effectiveness for neuropathic pain in a patient with glossopharyngeal neuralgia].

Kouzaki Y, Takita T, Tawara S, Otsuka T, Hirano T, Uchino M.

Rinsho Shinkeigaku. 2009 Jun;49(6):364-9. Japanese.

PMID:
19618847
19.

Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension.

Do e Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, Tada T, Saji K, Sugimura K, Fujita H, Hoshikawa Y, Nawata J, Kondo T, Shimokawa H.

Circ J. 2009 Sep;73(9):1731-9. Epub 2009 Jul 9.

20.

Dietary vitamin E deficiency increases anxiety-related behavior in rats under stress of social isolation.

Okura Y, Tawara S, Kikusui T, Takenaka A.

Biofactors. 2009 May-Jun;35(3):273-8. doi: 10.1002/biof.33.

PMID:
19472364
21.

Correspondence between neurological deficit, cerebral infarct size, and Rho-kinase activity in a rat cerebral thrombosis model.

Kawasaki K, Yano K, Sasaki K, Tawara S, Ikegaki I, Satoh S, Ohtsuka Y, Yoshino Y, Kuriyama H, Asano T, Seto M.

J Mol Neurosci. 2009 Sep;39(1-2):59-68. doi: 10.1007/s12031-009-9175-x. Epub 2009 Jan 23.

PMID:
19165632
22.

Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors.

Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H.

Circ J. 2009 Feb;73(2):361-70. Epub 2008 Dec 8.

23.

Demonstration of elevation and localization of Rho-kinase activity in the brain of a rat model of cerebral infarction.

Yano K, Kawasaki K, Hattori T, Tawara S, Toshima Y, Ikegaki I, Sasaki Y, Satoh S, Asano T, Seto M.

Eur J Pharmacol. 2008 Oct 10;594(1-3):77-83. doi: 10.1016/j.ejphar.2008.07.045. Epub 2008 Jul 31.

PMID:
18703046
24.

Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds.

Maki K, Matsumoto S, Watabe E, Iguchi Y, Tomishima M, Ohki H, Yamada A, Ikeda F, Tawara S, Mutoh S.

Microbiol Immunol. 2008 Aug;52(8):383-91. doi: 10.1111/j.1348-0421.2008.00053.x.

25.

Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats.

Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Shinozaki T, Kagaya Y, Shimokawa H.

J Cardiovasc Pharmacol. 2008 Mar;51(3):317-26. doi: 10.1097/FJC.0b013e31816533b7.

PMID:
18356698
26.

Direct comparison of the pharmacodynamics of four antifungal drugs in a mouse model of disseminated candidiasis using microbiological assays of serum drug concentrations.

Maki K, Holmes AR, Watabe E, Iguchi Y, Matsumoto S, Ikeda F, Tawara S, Mutoh S.

Microbiol Immunol. 2007;51(11):1053-9.

27.

Tetanus caused by ulcerated giant phyllodes tumor.

Yamashita S, Karashima R, Tsushima A, Tawara S, Kawahara K.

Breast J. 2007 Nov-Dec;13(6):614-5.

PMID:
17983406
28.

Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats.

Tawara S, Fukumoto Y, Shimokawa H.

J Cardiovasc Pharmacol. 2007 Aug;50(2):195-200.

PMID:
17703136
29.

Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.

Fukumoto Y, Tawara S, Shimokawa H.

Tohoku J Exp Med. 2007 Apr;211(4):309-20. Review.

30.

Progress of the study of rho-kinase and future perspective of the inhibitor.

Tawara S, Shimokawa H.

Yakugaku Zasshi. 2007 Mar;127(3):501-14. Review.

31.

Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.

Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H.

J Cardiovasc Pharmacol. 2007 Feb;49(2):85-9.

PMID:
17312448
32.

Effect of various radical generators on insulin-dependent regulation of hepatic gene expression.

Kimura K, Tawara S, Igarashi K, Takenaka A.

Biosci Biotechnol Biochem. 2007 Jan;71(1):16-22. Epub 2007 Jan 7.

33.

Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice.

Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, Kaibuchi K, Shimokawa H.

J Cardiovasc Pharmacol. 2006 Dec;48(6):280-5.

PMID:
17204906
34.

Determination of antifungal activities in serum samples from mice treated with different antifungal drugs allows detection of an active metabolite of itraconazole.

Maki K, Watabe E, Iguchi Y, Nakamura H, Tomishima M, Ohki H, Yamada A, Matsumoto S, Ikeda F, Tawara S, Mutoh S.

Microbiol Immunol. 2006;50(4):281-92.

35.

Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.

Yoshida Y, Matsuda K, Sasaki H, Matsumoto Y, Matsumoto S, Tawara S, Takasugi H.

Bioorg Med Chem Lett. 2004 May 17;14(10):2627-31.

PMID:
15109666
36.

In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.

Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M.

Antimicrob Agents Chemother. 2003 Apr;47(4):1376-81.

37.

In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds.

Nakai T, Uno J, Otomo K, Ikeda F, Tawara S, Goto T, Nishimura K, Miyaji M.

Chemotherapy. 2002 May;48(2):78-81.

PMID:
12011539
38.

Orally active cephalosporins. Part 4: synthesis, structure--activity relationships and oral absorption of novel 3-(4-pyrazolylmethylthio)cephalosporins with various C-7 side chains.

Yamamoto H, Eikyu Y, Okuda S, Kawabata K, Takasugi H, Tanaka H, Matsumoto S, Matsumoto Y, Tawara S.

Bioorg Med Chem. 2002 May;10(5):1535-45.

PMID:
11886815
39.

Antibacterial activity of cefixime against Salmonella typhi and applicability of Etest.

Matsumoto Y, Ikemoto A, Tawara S.

J Infect Chemother. 1999 Sep;5(3):176-179.

PMID:
11810512
40.

Mechanism of therapeutic effectiveness of cefixime against typhoid fever.

Matsumoto Y, Ikemoto A, Wakai Y, Ikeda F, Tawara S, Matsumoto K.

Antimicrob Agents Chemother. 2001 Sep;45(9):2450-4.

41.

Synthesis and antibacterial activity of novel 4-pyrrolidinylthio carbapenems Part IV. 2-Alkyl substituents containing cationic heteroaromatics linked via a C-C bond.

Zam HA, Barrett D, Tanaka A, Sasaki H, Matsuda K, Sakurai M, Terasawa T, Shirai F, Chiba T, Matsumoto Y, Tawara S.

Bioorg Med Chem. 2001 Apr;9(4):961-82.

PMID:
11354680
42.

Orally active cephalosporins. Part 3: synthesis, structure-activity relationships and oral absorption of novel C-3 heteroarylmethylthio cephalosporins.

Yamamoto H, Terasawa T, Nakamura A, Kawabata K, Takasugi H, Tanaka H, Matsumoto S, Matsumoto Y, Tawara S.

Bioorg Med Chem. 2001 Feb;9(2):465-75.

PMID:
11249138
43.

FR192752, a novel orally active cephalosporin synthesis and biological properties.

Yamamoto H, Kawabata K, Tawara S, Takasugi H, Tanaka H.

J Antibiot (Tokyo). 2000 Oct;53(10):1223-7. No abstract available.

44.

Studies on anti-Helicobacter pylori agents. Part 2: new cephem derivatives.

Yoshida Y, Matsuda K, Sasaki H, Matsumoto Y, Matsumoto S, Tawara S, Takasugi H.

Bioorg Med Chem. 2000 Sep;8(9):2317-35.

PMID:
11026544
45.

Orally active cephalosporins: synthesis, structure-activity relationships and oral absorption of 3-[(E) and (Z)-2-substituted vinyl]-cephalosporins.

Yamamoto H, Terasawa T, Ohki A, Shirai F, Kawabata K, Sakane K, Matsumoto S, Matsumoto Y, Tawara S.

Bioorg Med Chem. 2000 Jan;8(1):43-54.

PMID:
10968263
46.

Orally active cephalosporins. Part 2: synthesis, structure-activity relationships and oral absorption of cephalosporins having a C-3 pyridyl side chain.

Yamamoto H, Terasawa T, Nakamura A, Kawabata K, Sakane K, Matsumoto S, Matsumoto Y, Tawara S.

Bioorg Med Chem. 2000 May;8(5):1159-70.

PMID:
10882026
47.

Synthesis and biological properties of a novel cephalosporin FR86521 having potent activity against methicillin-resistant Staphylococcus aureus (MRSA)

Kishi K, Ohki H, Okuda S, Kawabata K, Sakane K, Matsumoto Y, Matsumoto S, Tawara S.

J Antibiot (Tokyo). 1999 Dec;52(12):1152-5. No abstract available.

48.

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.

Matsumoto S, Wakai Y, Nakai T, Hatano K, Ushitani T, Ikeda F, Tawara S, Goto T, Matsumoto F, Kuwahara S.

Antimicrob Agents Chemother. 2000 Mar;44(3):619-21.

49.

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.

Ikeda F, Wakai Y, Matsumoto S, Maki K, Watabe E, Tawara S, Goto T, Watanabe Y, Matsumoto F, Kuwahara S.

Antimicrob Agents Chemother. 2000 Mar;44(3):614-8.

50.

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, Goto T, Tomishima M, Ohki H, Yamada A, Kawabata K, Takasugi H, Sakane K, Tanaka H, Matsumoto F, Kuwahara S.

Antimicrob Agents Chemother. 2000 Jan;44(1):57-62.

Supplemental Content

Loading ...
Support Center